trial · primary record
Benralizumab
Asthma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 230 |
| Primary completion | 2029-12-27 |
| Primary endpoint | Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab |
| Registry ID | NCT07444567 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:44.577Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07444567
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.